Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W. C., Uhl, S., Hoagland, D., Moller, R., et al., 2020. Imbalanced host response to SARS-CoV–2 drives development of COVID–19. Cell. 181, 1036–1045.
Bellingan, G., Maksimow, M., Howell., D.C., Stotz, M., Beale, R., Beatty, M., et al., 2014. The effect of intravenous interferon-beta–1a (FP–1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir. Med. 2: 98–107.
Caly, L., Druce, J. D., Catton, M., Jans, D. A., Wagstaff, M., 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV–2 in vitro. Antiviral Res. 178, 104787. DOI: 10.1016/j.antiviral.2020.104787
Ciliberto, G., Mancini, R., Paggi, MG. 2020. Drug repurposing against COVID–19: focus on anticancer agents. J. Exp Clin Canc Res. 39, 86. DOI: 10.1186/s13046–020–01590–2
Deng, X., Hackbart, M., Mettelman, R. C., O’Brien, A., Mielech, A.M., Yi, G., et. al., 2017. Coronavirus nsp15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. PNAS. 114, E4251-E4260.
Doncheva, N. T., Morris, J. H., Gorodkin J, Jensen, L., 2019. Cytoscape stringapp: network analysis and visualization of proteomics data. J. Proteome Res. 18, 623–632.
Feng, Y., Ni, L., Wan, H., Fan, L., Fei, X., Ma, Q., et al., 2011. Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep. 26, 1157–64.
GeneCards. 2020. GeneCards: the human gene database. Available at: https://www.genecards.org/ (Accessed June 22, 2020).
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., et al., 2020. A SARS-CoV–2 protein interaction map reveals targets for drug repurposing. Nature. (Published online 30 April 2020). DOI 10.1038/s41586–020–2286–9
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, E., et al., 2020. Compassionate use of remdesivir for patients with severe Covid–19. N. Engl. J. Med. 382, 2327–2336.
Guy, R. K., DiPaola, R. S., Romanelli, F., Dutch, R. E., 2020. Rapid repurposing of drugs for COVID–19. Science 368, 829–830. DOI: 10.1126/science.abb9332
Human Protein Atlas: Version 9.3., 2020. Available at: https://www.proteinatlas.org/ (Accessed June 22, 2020).
Huber, W., Carey, V.J., Gentleman, R., Anders, S., Carlson, M., Carvalho, B. S., et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nature Methods. 2015; 12(2): 115–121.
Josh, R. J., Manuel, A., 2020. COVID–19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir. Med. 8, E46-E47.
Khalil RA, Morgan, K. G., 1996. Enzyme translocations during smooth muscle activation, In Biochemistry of Smooth Muscle Contraction, 307–318. DOI: 10.1016/B978–012078160–7/50027–5
Kim, D., Lee, J. Y., Yang, J. S., Kim, J. W., Kim, V. N., Chang, H., 2020. The architecture of SARS-CoV–2 transcriptome. Cell 181, 914–921.
Kumari, N., Dwarakanath, B. S., Das, A., Bhatt, A. N., 2016. Role of interleukin–6 in cancer progression and therapeutic resistance. Tumor Biol. 37, 11553–11572.
Li, G., Clercq, D. E., 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149–50.
Liao, Y., Wang, X., Huang, M., Tam, J. P., Liu, D. X., 2011. Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus. Virology 420, 106–116.
Mick, E., Kamm, J., Pisco, A. O., Ratnasiri, B. J. M., Calfee, C. S., Castaneda, G., et al. 2020. Upper airway gene expression differentiates COVID–19 from other acute respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV–2.medRxiv. (Posted May 22, 2020). DOI:10.1101/2020.05.18.20105171
Ouyang, Y., Yin, J., Wang, W., Shi, H., Shi, Y., Xu, B., et al., 2020. Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID–19 patients. Clin. Infect. Dis. ciaa462. DOI: 10.1093/cid/ciaa462 (Published online April 20, 2020).
Shaha, B., Modia, P., Sagara, S. R. 2020. In silico studies on therapeutic agents for COVID–19: drug repurposing approach. Life Sci. 252, 117652. DOI: 10.1016/j.lfs.2020.117652
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., et al., 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. GenomeRes. 13, 2498–2504.
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., et al. Cell entry mechanisms of SARS-CoV–2. PNAS. 117, 11727–11734.
Schett, G., Sticherling, M., Neurath, M. F., 2020. COVID–19: risk for cytokine targeting in chronic inflammatory diseases? Nat. Rev. Immunol. 20, 271–72.
Schoggins, J. M., Rice, C. M., 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opinion Virol. 1: 519–525.
Surjit, M., Liu, B., Chow, V. T., Lal, S. K., 2006. The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells. J. Biol. Chem. 281, 10669–10681.
Uno, Y., 2020. Camostat mesilate therapy for COVID19. Intern. Emerg. Med. (Published online April 29, 2020). DOI: 10.1007/s11739–020–02345–9
Vara, J. A. F., Casado, E., Castro, J., Cejas, P., Belda-Iniesta, C., Gonzalez-Baron, M., 2004. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193–204.
Wathelet, M. G., Orr, M., Frieman, M. B., Baric, R. S., 2007. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol. 81, 1620–11633.
WikiPathways. 2020. Portal: disease/COVID pathways (June 22, 2020). Available at: https://www.wikipathways.org/index.php/Portal:Disease/COVIDPathways (Accessed June 22, 2020).
World Health Organization. WHO coronavirus disease (COVID–19) dashboard. WHO 2020. Available at: https://covid19.who.int/ (Accessed June 26, 2020).
Wu, C. H., Chen, P. J., Yeh, S. H., 2014. Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables coronavirus transition from discontinuous to continuous transcription. Cell Host Microbe 16, 462–472.
Wu, R., Wang, L., Kuo, H. C. D., Shannar, A., Peter, R., Chou, P. J., et al., 2020. An update on current therapeutic drugs treating COVID–19. Curr Pharmacol Rep 6, 56–70.